このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発性AMLまたはMDS患者におけるMT-401-OTSの安全性 (RAPID)

2026年11月9日 更新者:Marker Therapeutics, Inc.

再発性急性骨髄性白血病または骨髄異形成症候群(RAPID)の患者に投与される既製の同種多腫瘍関連抗原特異的T細胞製品(MT-401-OTS)の第1相試験

This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or </= 10% blast following prior induction therapy or at least 4 cycles of nonintensive therapy and 2) those with high- or very-high-risk MDS per 2023 IWG criteria and who have residual disease with </= 10% blasts following treatment with an HMA-based therapy.

調査の概要

状態

募集

介入・治療

詳細な説明

This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or </= 10% blast following prior induction therapy or at least 4 cycles of nonintensive therapy and 2) those with high- or very-high-risk MDS per 2023 IWG criteria and who have residual disease with </= 10% blasts following treatment with an HMA-based therapy. Participants must meet all eligibility criteria. Once a suitable MT-401-OTS product is confirmed, the participant will receive a lymphodepleting conditioning regimen consisting of fludarabine and cyclophosphamide daily from Day -7 to Day -5. Bendamustine (administered on Days -6 and -5) may be used for participants with underlying toxicities or if lack of availability precludes the use of fludarabine and/or cyclophosphamide. Two standard doses of an HMA (azacitidine or decitabine) will be administered on Day -4 to -3. MT-401-OTS will be administered IV over 10 minutes on Day 0. Safety evaluations will be performed throughout the study. Disease assessments will be performed at regular intervals based on 2022 ELN criteria for AML and the 2023 response criteria for higher-risk MDS. The dose escalations will begin with Cohort 1 which a single MT-401-OTS dose administered at a flat dose of 100 X 10^6 cells). Dose escalations will proceed using the modified 3+3 design up to the highest single flat dose of 400 x 10^6 cells. If a clinical safety issue should arise in Cohort 1, a lower DL may be explored. Additionally, Cohort 4 is an optional cohort that may be considered based on the cumulative data from Cohorts 1 through 3 to asses alternative dosing schedules (split dosing) of 400 X 10^ 6 cells or without lymphodepletion and/or HMA.

研究の種類

介入

入学 (推定)

40

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • California
      • Duarte、California、アメリカ、91006
        • 募集
        • City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center)
        • 主任研究者:
          • Shukaib Arslan, MD
        • コンタクト:
    • Florida
      • Tampa、Florida、アメリカ、33612
        • 募集
        • Moffitt Cancer Center
        • 主任研究者:
          • Nelli Bejanyan
        • コンタクト:
    • Kansas
      • Kansas City、Kansas、アメリカ、66160
        • 募集
        • KU Cancer Center
        • コンタクト:
        • 主任研究者:
          • Haitham Abdelhakim

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

65年歳以上 (高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • General

    1. Must be ≥ 65 years of age and capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol, at the time of signing the ICF

    2. Must have a life expectancy ≥ 12 weeks

    3. Must have an ECOG performance status of 0-2

    4. Must have available MT-401-OTS product with a ≥ 2/8 HLA match Disease Characteristics

    5. For participants with AML:

      1. Must have a confirmed diagnosis of AML or MDS/AML per 2022 WHO Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms or 2022 International Consensus Criteria
      2. Must have intermediate or high-risk disease based on ELN 2022 criteria.
      3. If no targetable mutation is present, must have received 1 prior standard regimen with at least 4 cycles of standard therapy containing an HMA or a standard cytarabine-containing induction therapy
      4. If targetable mutation is present, must have received a regimen that includes commercially available targeted therapy unless unable to tolerate or the participant declines (must be documented in the informed consent). If targeted therapy was not administered as part of first-line of therapy, a second regimen is allowed.
      5. Must have either: ≤ 10% bone marrow blasts and ≤ 5% peripheral blasts during screening and not be considered to have hyperproliferating disease at diagnosis or after treatment OR Evidence of MRD based on evaluation at a local laboratory
    6. For participants with MDS:

      1. Must have confirmed diagnosis of MDS based on 2022 WHO Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms or 2022 ICC criteria
      2. Must have high-risk or very-high-risk disease based on IPSS-M (ie, not evolved to AML)
      3. Must have received standard treatment with at least 4 cycles of an HMA and have evidence of continued disease, including morphologic disease or MRD-positive
      4. Must have bone marrow blasts ≤ 10% at screening Health Status
    7. Must have adequate coagulation, hepatic, renal, and cardiac function:

      1. PT/INR and PTT/aPTT < 1.3 × ULN
      2. AST and ALT < 3 × ULN; for participants with leukemic infiltration of the liver (documented by biopsy or imaging), AST and ALT < 5 × ULN is permitted.
      3. Total bilirubin ≤ 1.5 × ULN unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin (2 × ULN is permitted)
      4. eGFR ≥ 40 mL/min by the MDRD formula
      5. LVEF ≥ 45% (prior to apheresis and lymphodepletion) Sex
    8. Women of childbearing potential are eligible to participate if they agree to the following during the intervention period and for at least 1 year after the last infusion of MT-401-OTS:

      1. Must use a contraceptive method that is highly effective (ie, with a failure rate of < 1% per year; see Section 10.3), preferably with low user dependency PLUS
      2. Must agree not to donate eggs (ie, ova and oocytes) for the purpose of reproduction
    9. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 6 months after the last infusion of MT-401-OTS:

      1. Must refrain from donating sperm

        PLUS either:

      2. Must be abstinent from intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR

      3. Must agree to use a male condom AND should also be advised of the benefit for a nonpregnant female partner to use a highly effective method of contraception (see Section 10.3) as a condom may break or leak

Exclusion Criteria:

  • Disease-Related

    1. Have leukemic involvement in the CNS

    2. Have other extramedullary disease involvement (except hepatosplenic involvement)

    3. Have APL Medical Conditions

    4. Have primary immunodeficiency

    5. Have severe or uncontrolled autoimmune disorder

    6. Have a history or presence of clinically relevant CNS pathology, such as epilepsy, seizure, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome or psychosis

    7. Have active malignancies (ie, those that are progressing or have required treatment change in the last 24 months) other than the disease being treated under study. Exceptions to this inclusion include the following:

      1. Nonmelanoma skin cancer treated within the last 24 months that is considered completely cured
      2. Adequately treated breast lobular carcinoma in situ and breast ductal carcinoma in situ
      3. Adequately treated cervical carcinoma in situ without evidence of disease
      4. History of localized breast cancer and receiving antihormonal agents, or history of localized prostate cancer (N0M0) and receiving androgen-deprivation therapy
      5. A malignancy that is considered cured with minimal risk of recurrence
    8. Have any active systemic infection requiring therapy (viral, bacterial, or fungal), including HIV

    9. Have active hepatitis B or C infection or other clinically active liver diseases, as defined below:

      1. Seropositivity for hepatitis B as defined by a positive test for HbsAg Participants with resolved infection (ie, participants who are HbsAg-negative with antibodies to total anti-HBc with or without the presence of anti-HBs) must be screened using RT-PCR measurement of HBV DNA levels. Those who are RT PCR-positive will be excluded.

        Participants with serologic findings suggestive of HBV vaccination (anti HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by RT PCR.

      2. Active hepatitis C infection as defined by being positive for a nucleic acid test for HCV RNA

    10. Have Class III or IV congestive heart failure per New York Association

    11. Have unstable angina

    12. Have a history or evidence of current, uncontrolled, clinically significant, unstable arrhythmias

    13. Have an oxygen saturation on room air of ≤ 92%

    14. Have clinically significant reversible nonhematologic toxicities from prior cancer therapy that have not recovered to Grade 1 or baseline Note: Participants with clinically nonsignificant toxicities, such as asymptomatic laboratory values, will be allowed on study.

      Prior/Concomitant Therapies

    15. Received prior treatments for underlying malignancy, except as specified in the Inclusion Criteria. Participants with AML secondary to MDS may have received prior treatment for MDS.

    16. Have had prior HSCT

    17. Are receiving concurrent therapies other than HMA, as delineated in the study design

    18. Have received hematopoietic growth factors within 2 days of lymphodepleting conditioning regimen

    19. Have a history of severe allergic reactions/intolerance to any of the study intervention components, including the conditioning regimen, HMA, or DSMO, or to tocilizumab

    20. Have had major surgery within 14 days (central line placement allowed)

    21. Have received systemic steroids (exception: physiological doses of steroids allowed) or other immunosuppressive therapies within 14 days prior to lymphodepleting conditioning regimen Other

    22. Are unable to be matched with MT-401-OTS product inventory

    23. Are pregnant or breastfeeding

    24. Have any other issue that, in the opinion of the treating physician, would make the participant ineligible for the study or unable to comply with its requirements

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort -1

50 × 106 cells flat dose, 1 dose infused on Day 0

MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

実験的:Cohort 1

100 × 106 cells flat dose, 1 dose infused on Day 0

MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

実験的:Cohort 2

200 × 106 cells flat dose, 1 dose infused on Day 0

MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

実験的:Cohort 3

400 × 106 cells flat dose, 1 dose infused on Day 0

MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

実験的:Cohort 4 (optional)

up to 400 × 106 cells flat dose TBD based on data from Cohorts 1-3; may include split dosing, dosing with or without lymphodepleting conditioning regimen, or dosing with or without HMA

MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety of MT-401-OTS
時間枠:Through study completion. Approximately 5 years

Assess:

  • Incidence of DLTs to determine the RP2D
  • Safety (including but not limited to): TEAEs, SAEs, deaths, and clinical laboratory abnormalities per NCI CTCAE, Version 5.0
  • Acute GVHD per 2016 MAGIC criteria
  • CRS and ICANS per ASTCT criteria
Through study completion. Approximately 5 years
Tolerability of MT-401-OTS
時間枠:Through study completion. Approximately 5 years

cGVHD per 2014 NIH consensus criteria for cGVHD

Through study completion. Approximately 5 years

二次結果の測定

結果測定
メジャーの説明
時間枠
To assess the efficacy of MT-401-OTS in participants with high-risk or very-high-risk MDS per IPSS-M who have evidence of disease following at least 4 cycles of a HMA
時間枠:Following conclusion of the disease assessment of last MDS subject treated. Approximately 2 years

Per 2023 IWG criteria for higher-risk MDS:

  • CR rate
  • DOCR
  • ORR
  • DOR
Following conclusion of the disease assessment of last MDS subject treated. Approximately 2 years
To assess the efficacy of MT-401-OTS in participants with intermediate or high-risk AML per 2022 ELN criteria who have evidence of disease following induction therapy or at least 4 cycles of nonintensive treatment
時間枠:Following conclusion of the disease assessment of last AML subject treated. Approximately 2 years

Per 2022 ELN Criteria for AML:

  • Rate of MRD negativity
  • CR, DOCR
  • ORR, DOR
Following conclusion of the disease assessment of last AML subject treated. Approximately 2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年6月16日

一次修了 (推定)

2029年9月1日

研究の完了 (推定)

2029年9月1日

試験登録日

最初に提出

2024年8月7日

QC基準を満たした最初の提出物

2024年8月9日

最初の投稿 (実際)

2024年8月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2025年12月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • MRKR-21-401-OTS
  • 5R01FD007272-02 (米国FDA認可/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

IPD sharing plan will be developed once it is determined that the results of this study may be published or presented at scientific meetings.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する